Compare PFO & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFO | DTIL |
|---|---|---|
| Founded | 1991 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.3M | 136.0M |
| IPO Year | N/A | 2019 |
| Metric | PFO | DTIL |
|---|---|---|
| Price | $9.28 | $6.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 29.3K | ★ 353.9K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 6.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,070,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.01 | $3.53 |
| 52 Week High | $9.90 | $8.82 |
| Indicator | PFO | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 56.53 | 63.59 |
| Support Level | $9.16 | $4.50 |
| Resistance Level | $9.33 | $7.59 |
| Average True Range (ATR) | 0.11 | 0.52 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 81.03 | 80.76 |
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).